Performance of Plasma HSP90α, Serum EBV VCA IgA Antibody and Plasma EBV DNA for the Diagnosis and Prognosis Prediction of Nasopharyngeal Carcinoma

作者：Qiang Ye, Jun Guo, Yue Chen, Cui Z, Yue Chen · 发表于：DOAJ (DOAJ: Directory of Open Access Journals) · 年份：2021 · 研究领域：Viral-associated cancers and disorders、Respiratory viral infections research、Lymphoma Diagnosis and Treatment

Qian Ye, Junying Guo, Yansong Chen, Zhaolei Cui, Yan Chen Department of Laboratory Medicine, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou City, Fujian Province, 350014, People’s Republic of ChinaCorrespondence: Zhaolei Cui; Yan ChenDepartment of Laboratory Medicine, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No. 420 Fuma Road, Jin’an District, Fuzhou City, Fujian Province, 350014, People’s Republic of ChinaEmail cuileidizi@163.com; chenyan220422@fjmu.edu.cnObjective: The aim of this study was to evaluate the effectiveness of Epstein–Barr virus (EBV) VCA-IgA antibody, EBV DNA and HSP90α alone or in combinations for the diagnosis and prognostic prediction of nasopharyngeal carcinoma (NPC).Methods: A total of 113 treatment-naïve patients with NPC and 40 healthy controls were enrolled. Plasma HSP90α and serum EBV VCA IgA antibody were detected using ELISA, and plasma EBV DNA was quantified using qPCR assay. The effectiveness of plasma HSP90α level, serum EBV VCA IgA antibody and plasma EBV DNA was examined in the diagnosis and prognosis prediction of NPC.Results: Higher plasma HSP90α, serum EBV VCA IgA antibody and plasma viral load of EBV DNA were detected in NPC patients than in healthy controls (P < 0.001). The plasma HSP90α levels, serum EBV VCA IgA antibody titers and plasma viral load of EBV DNA were significantly greater in NPC patients with stages III and IV than in those with stages I and II (P < 0.001), and significan...